First Patient Dosed In Ph 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3
“Dosing of the first patient in this Phase 1/2 study of FPI-1966 demonstrates our continued ability to bring innovative targeted alpha therapies (TATs) into the clinic,” said Chief Executive Officer John Valliant, Ph.D. “This study will evaluate FPI-1966 in patients with solid tumors expressing FGFR3, a validated cancer target found in multiple tumor types with substantial unmet need, notably bladder, ovarian and head and neck cancers. FPI-1966, and the growing number of TATs in our pipeline, are designed as next generation antibody drug conjugates (ADCs) in that they leverage the potency of actinium-225 and alpha particle radiation in place of chemical toxins to selectively eradicate cancer cells. Given the prevalence of the FGFR3 target, and the use of a precision medicine approach that employs an imaging analogue to enable patient selection, we believe FPI-1966 has the potential to become an important new treatment paradigm for cancer patients.”
Share:
More News
“Antengene announced it has entered into a global clinical collaboration with MSD to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate (ADC), and MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), Antengene
“Advanced esophageal squamous cell carcinoma is a difficult-to-treat disease, and unfortunately overall survival remains low,” said Marjorie Green, MD, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “The initiation of the pivotal Phase 3 IDeate-Esophageal01 clinical trial demonstrates our shared commitment with Daiichi Sankyo to
“Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (>VGPR) rate of 85% (100/117), per International Myeloma Working Group (IMWG) criteria as investigator-assessed. Of those evaluable for minimal residual disease (MRD) testing at
“EMA approval of the MIRACLE trial protocol is a huge milestone for us. Although we’re already seeing recruitment in our first non-EU country, we believe that this expansion into the EU really supercharges our recruitment potential,” said Walter Klemp, Chairman and CEO of Moleculin. “Importantly, when combined with the sites
